Alkermes: FORM 8.1(a) & (b) (Opening Position Disclosure)

Alkermes: FORM 8.1(a) & (b) (Opening Position Disclosure)

November 05, 2025 | Last Trade: US$29.04 1.97 -6.35

DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS):

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE

1. KEY INFORMATION

(a)	Full name of discloser:	Alkermes plc
(b)	Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.	N/A
(c)	Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree	Avadel Pharmaceuticals plc
(d)	Is the discloser the offeror or the offeree?	OFFEROR
(e)	Date position held: The latest practicable date prior to the disclosure	3 November 2025
(f)	In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A"	N/A

2. INTERESTS AND SHORT POSITIONS

If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1)

N/A

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. INTERESTS AND SHORT POSITIONS OF PERSONS ACTING
IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE

Details of any interests and short positions (including directors' and other employee options) of any person acting in concert with the party making the disclosure:
Interests of J.P. Morgan (together with its members of staff under Rule 3.3(b)(v) of Part A of the Irish Takeover Rules), financial advisors to Alkermes plc, but, for clarity, not held on behalf of Alkermes plc:
	Party	Class of Relevant Security	Number of ordinary shares held at midnight (ET) on 3 November 2025	Percentage of total issued share capital (rounded)
	55I, LLC	Ordinary shares of US$0.01 each	53	0.0001 %
	JPMorgan Chase Bank, National Association	Ordinary shares of US$0.01 each	13,500	0.0139 %
	TOTAL		13,553	0.0139 %



Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

Ap11

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement
or understanding, formal or informal, relating to relevant securities
which may be an inducement to deal or refrain from dealing entered
into by the party to the offer making the disclosure or any person
acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If
there are no such agreements, arrangements or understandings, state
"none"

None

(b) Agreements, arrangements or understandings
relating to options or derivatives

Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.

None

(c) Attachments

Is a Supplemental Form 8 attached?	YES/NO
	No

Date of disclosure:	5 November 2025
Contact name:	Sandy Coombs, Alkermes
Telephone number:	+1 781 609 6377

Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.

Ap12

NOTES ON FORM 8.1(a) and (b)

See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.
See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Stock Quote

Last Trade:	US$29.04
Daily Change:	-1.97 -6.35
Daily Volume:	4,388,666
Market Cap:	US$4.800B

November 12, 2025 Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 October 28, 2025 Alkermes Reports Third Quarter 2025 Financial Results October 22, 2025 Alkermes Announces Agreement to Acquire Avadel Pharmaceuticals September 08, 2025 Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 August 25, 2025 Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE